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ORIGINAL ARTICLE
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Pathanapitoon, MD, PHD1, and Aniki Rothova, MD, PHD2
1Department of Ophthalmology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand,
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ABSTRACT
Purpose: To describe risk factors for development of rhegmatogenous retinal detachment (RRD) in patients with
uveitis.
Methods: We performed a retrospective review of 411 consecutive human immunodeficiency virus-negative
patients with uveitis (571 affected eyes) and report on prevalence, risk factors and visual outcomes of patients
with RRD.
Results: Prevalence of RRD was 7% of all patients with uveitis. Multivariate analysis revealed that posterior
uveitis and panuveitis were associated with RRD (P = 0.001). Strong association between RRD development and
infectious uveitis was also observed (P = 0.009). Acute retinal necrosis (ARN) was firmly associated with RRD
development (P = 0.016). Although anatomical success was obtained, functional outcome was poor. Poor visual
outcomes at 6-month and 1-year follow-up were associated with initial VA < counting fingers (P = 0.05,
P = 0.044).
Conclusions: Prevalence of RRD in uveitis was 7% and development of RRD was encountered in posterior and
panuveitis. Infectious uveitis (specifically ARN) formed a high risk for RRD.
Keywords: Prevalence, rhegmatogenous retinal detachment, Thailand, uveitis, visual outcome
Retinal detachment (RD) represents a serious compli-
cation of uveitis and is commonly associated with
limited visual outcome. All three forms of RD (exuda-
tive, rhegmatogenous, and tractional) can develop
during the course of uveitis. Previously, the incidence
of rhegmatogenous RD (RRD) in uveitis was reported
to be 3.1% in contrast to 0.01% of RRD identified in the
general population.1–3
Development of RRD can be enhanced by inflamma-
tory complications such as posterior vitreous detachment
(PVD), morphological changes within vitreous base espe-
cially following intermediate uveitis. Inflammation can
destroy retinal cells and weaken the intercellular adhe-
sions of the retinal cells and pigment epithelium result-
ing in higher rate of retinal breaks.4,5
The visual prognosis of RRD in uveitis was reported
to be worse than RRD without uveitis despite similar
surgical treatments, presumably due to multiple fac-
tors such as young age, higher prevalence of prolifera-
tive vitreoretinopathy (PVR) before and after the
surgery as well as the presence of diverse complica-
tions of uveitis such as macular edema, glaucoma,
hypotony, cataract, and retinal scars.1,6–10
The purpose of this study is to report on the risk
factors for development of RRD in human immunodefi-
ciency virus (HIV)-negative patients with uveitis as well
as to report on the visual outcomes after the surgery.
METHODS
We conducted a retrospective analysis of the medical
records of 411 consecutive uveitis patients visiting an
outpatient Ophthalmology Department of Chiang Mai
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University Hospital from January 2013 through
December 2015. The medical data of all patients were
reviewed and patients with RRD were identified.
Patients with diagnosis of RRD before the onset of
uveitis and patients with HIV infection were not
included as the high prevalence of RRD in cytomega-
lovirus retinitis might strongly affect the results for
general uveitis.11–14 We collected demographic data
of the patients including gender, age at onset of RRD,
laterality, the interval between the onset of uveitis and
the occurrence of RRD, inflammatory activity at the
onset of RRD, visual acuity (VA) at onset of RRD, the
nature of breaks, the extent of RRD, the presence of
PVR, previous intraocular surgery and duration of
follow-up. The data concerning uveitis such as its
onset, anatomical classification, specific uveitic entities,
cause or association with systemic disease were also
noted. In addition, surgical technique, visual outcome
after surgery and VA after surgery, reattachment rate
and complication were registered.
Complete anatomic success was considered if the
whole retina was reattached after the operation, and
the term “partial success” was used if the retina
including the macular area was attached, though the
peripheral inferior retina was still detached.
VA was tested using Snellen acuity chart and con-
verted to Early Treatment Diabetic Retinopathy Study
(ETDRS) letter scores for all calculations and statistical
analyses.15 Student’s t-test, Mann–Whitney U test,
Kruskal–Wallis tests, and ANOVA tests were used for
continuous variables and Fisher exact test or Pearson’s
chi-square test were used for categorical variables by a
software package, SPSS 17.0 (SPSS Inc., Chicago, IL,
USA). A significance level of 5% was used.
The study was approved by the Ethics Committee
of Chiang Mai University Hospital and performed in
agreement with the Declaration of Helsinki.
RESULTS
Our study included 411 patients (571 eyes affected by
uveitis) consisting of 205 females (49.9%) and 206
males (50.1%). The patient demographics and specific
uveitis entities are given in Tables 1 and 2. The pre-
valence of RRD in patients with uveitis was 7% (28/
411; 5%; 29/571 of affected eyes). RRD occurred within
a year after diagnosis of uveitis in all patients and in
23/28 patients (82%) within 3 months.
Total RRD was present in 21/28 patients (75%) and
5 patients (18%) developed proliferative vitreoretino-
pathy before surgery. We encountered a horseshoe
tear in 15/29 eyes (52%) and atrophic round holes in
atrophic and/or necrotic retina in 14/29 eyes (48%).
Multiples retinal breaks were observed in 11/29 eyes
(38%) whilst 18/29 eyes (62%) had 1 or 2 retinal
breaks. Majority of retinal breaks were located in the
peripheral retina (26/29, 90%). We found primary
RRD in 23/29 eyes (79%) and secondary RRD (retinal
breaks induced by traction which) in 6/29 eyes (21%).
Active inflammation at time of RRD onset was pre-
sent in 21/29 RRD eyes (72%). The VA at the first
presentation was worse in RRD group (P < 0.001).
Previous cataract surgery was performed in 2/29
eyes; 7% of RRD group and in 35/542 eyes; 7% of
non-RRD uveitis patients. Previous diagnostic vitrect-
omy was performed in 15 eyes, all of which were in
non-RRD patients.
Using univariate analysis, we found that posterior
uveitis (P = 0.038; OR 2.86 CI 1.192–6.859) and panu-
veitis (P < 0.001; OR 5.239 CI 2.3–11.937) were asso-
ciated with RRD. In addition, infectious uveitis and
specifically acute retinal necrosis (ARN) were asso-
ciated with the development of RRD (P = 0.009;
OR = 2.938, CI 1.353–6.379 and P = < 0.001;
OR = 11.385, CI 4.234–30.608, respectively).
TABLE 1. General characteristics of uveitic patients with and without rhegmatogenous retinal detachment.
Uveitic RRD Uveitis without RRD P-value
Patients (n = 411) 28 383 –
Laterality (unilateral:bilateral) 27:1 224:159 –
Eyes (n = 571) 29 542 –
Location (n = 411)
- Anterior uveitis (n = 177) 1(3.6%) 176 (46%) P < 0.001a
- Posterior uveitis (n = 55) 8 (28.6%) 47 (12.3%) P = 0.038b
- Intermediate uveitis (n = 50) 0 50 (13%) P = 0.036b
- Panuveitis (n = 129) 19 (67.8%) 110 (28.7%) P < 0.001a
Median age (years) at onset of uveitis (n = 411) 44.5
(range 13–78)
46
(range 3–83)
P = 0.589c
Male/female ratio 15:13 191:192 0.845d
Mean follow-up (months) 16 N/A –
RRD, rhegmatogenous retinal detachment
aContinuity correction.
bFisher’s exact test.
cMann–Whitney test.
dPearson chi-square test.
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Posterior and panuveitis associated with RRD exhib-
ited retinal vasculitis in 7/29 eyes (24%), choroiditis
3/29 eyes (10%), granuloma 3/29 eyes (10%), neo-
vascularization at disk or elsewhere in the retina in
3/29 eyes (10%), and necrotic retinal lesions 12/29
eyes (41%). Prior intravitreal injections were more
common in the RRD group (5/29 eyes; 17% versus
34/542 eyes; 6%; P = 0.04; OR = 3.113, CI 1.118–
8.668).
Multivariate analysis revealed that posterior uveitis
(P = 0.001; OR 34.022 CI 4.060–285.092), panuveitis
(P = 0.001; OR 29.559 CI 3.830–228.136), and ARN
(P = 0.016; OR = 5.057, CI 1.354–18.885) were risk
factors of RRD in patients with uveitis. Patients with
posterior and panuveitis had 10 times greater risk to
develop RRD compared to patients with anterior uvei-
tis (OR = 10.034, 95% CI 3.655–245.524 and
OR = 10.922, 95% CI 4.013–230.300, consecutively).
Age, sex and prior ocular surgery were not associated
with the RRD development. Using the multivariate
analysis, the association between the RRD and prior
intravitreal injections disappeared.
In patients with RRD, infectious etiology was pre-
sent in 54%, with ARN being the most common entity
(8/28, 29% of all; 8/15, 53% of infection; 8/21, 38% of
all with ARN) followed by toxocariasis (3/28, 11% of
all; 3/15, 20% of infection; 3/9, 33% of all with tox-
ocariasis) and toxoplasmosis (2/28, 7.1% of all; 2/15,
13.3% of infection; 2/27, 7.4% of all with toxoplasmo-
sis). The remainder of RRD patients had mostly uveitis
of undetermined origin (8/28, 28.6% of all; 8/13, 61.5%
of not proven infectious origin; 8/158, 5.1% of all with
undetermined cause of uveitis).
All 29 eyes with RRD underwent pars plana vitrect-
omy (PPV), with addition of scleral bucking in 10 eyes
and silicone oil tamponade in 19 eyes. During surgery,
oral steroid treatment was given to 18/28 (64%)
patients and one patient received immunosuppressive
therapy. Visual outcome is shown in Table 3. Although
anatomical success at 1-year follow-up was obtained in
90% of eyes, almost 75% of patients became legally
blind (VA less than 20/200). Six out of 19 eyes (32%)
had to retain long-term silicone oil tamponade due to
either hypotony and/or recurrence of RRD. However,
TABLE 2. Specific entities in patients with and without rhegmatogenous retinal detachment in uveitis.
Uveitic RRD
(n = 28)
Uveitis without RRD
(n = 383)
Infectious uveitis
Viral (n = 81) Herpetic AU (n = 33) 0 33 (8.6%)
ARN (n = 21) 8 (28.6%) 13 (3.4%)
CMVR (n = 27) 1 (3.6%) 26 (6.8%)
Parasitic (n = 37) Toxoplasma (n = 27) 2 (7.1%) 25 (6.5%)
Toxocara (n = 9) 3 (10.7%) 6 (1.6%)
Cysticercus (n = 1) 1 (3.6%) 0
Bacterial (n = 5) Tuberculosis (n = 5) 0 5 (1.3%)
Total (n = 123) 15 (53.6%) 108 (28.2%)
Non-infectious uveitis
Diagnosis Lymphoma (n = 3) 2 (7.1%) 1 (0.3%)
Behcet disease (n = 40) 1 (3.6%) 39 (10.2%)
VKH (n = 31) 2 (7.1%) 29 (7.6%)
HLA-B27 (n = 24) 0 24 (6.3%)
Sarcoidosis (n = 8) 0 8 (2.1%)
Fuchs uveitis (n = 13) 0 13 (3.4%)
Sympathetic ophthalmia (n = 3) 0 3 (0.8%)
Eales’ disease (n = 8) 0 8 (2.1%)
Undetermined (n = 158) 8 (28.6%) 150 (39.2%)
Total (n = 288) 13 (46.4%) 275 (71.8%)
RRD, rhegmatogenous retinal detachment; AU, anterior uveitis; ARN, acute retinal necrosis; CMVR, cytomegalovirus retinitis; VKH,
Vogt–Koyanagi–Harada; HLA-B27, human leukocyte antigen B27.
TABLE 3. Visual outcome of rhegmatogenous retinal detach-
ment in uveitis.
6-month follow-up
(n = 22)
1-year
follow-up
(n = 19)
Anatomical success
- Complete 16 (72.8%) 14 (73.7%)
- Partial 3 (13.6%) 3 (15.8%)
- Recurrent RRD 3 (13.6%) 2 (10.5%)
Visual outcome
- Improved 14 (63.7%) 10 (52.6%)
- Stable 5 (22.7%) 6 (31.6%)
- Worse 3 (13.6%) 3 (15.8%)
Visual outcome*
- BCVA ≥ 20/200 6 (27.3%) 5 (26.3%)
- BCVA ≤ CF 8 (36.4%) 12 (63.2%)
BCVA, best-corrected visual acuity; CF, counting fingers;
RRD, rhegmatogenous retinal detachment.
*Initial VA (n = 29): VA ≥ 20/200 in 5 (17.2%), VA ≤ CF in 23
(79.3%).
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some visual improvement after surgery occurred in
50–60% of eyes (Table 3).
Complication rate increased with the longer dura-
tion of follow-up. Out of the 19 eyes, which could be
evaluated at 1-year follow-up, cataract occurred in
42% and ocular hypertension or glaucoma in 37%;
one eye developed phthisis.
Visual outcomes of less than counting fingers at 6-
month and 1-year follow-up were associated with poor
VA at presentation with RRD (P = 0.05; OR 1.75 CI
1.112–2.755 and P = 0.044; OR 2.167 CI 1.204–3.898,
respectively)
DISCUSSION
In our study, the prevalence of RRD in uveitis popula-
tion was 7% and the risk factors for development of
RRD included posterior and panuveitis locations as
well as infectious origin of uveitis, with ARN being
the most common single uveitis entity.
The RRD prevalence in uveitis of 7% is higher than
in normal population and seems also higher than
3.1% reported earlier in uveitis population in
Europe.1–3 This difference might be explained by a
possible higher prevalence of infectious uveitis in
developing countries.11,16–23 The prevalence of infec-
tious uveitis was 30% in this study whilst 15–23% was
documented in previous the study from United States
and Europe. 1,24–26 Infectious uveitis (especially viral
infections) is usually associated with retinal necrosis
and subsequent atrophy combined with vitreous
degeneration, fibrosis, and traction, resulting in
development of retinal holes and finally detachment.
In addition, patients in Thailand possibly attended
the ophthalmologists in the later stage, which is illu-
strated by the fact that 75% of patients with RRD had
total RD and 80% of these patients had VA of count-
ing fingers or less at first presentation with RRD.
Posterior and panuveitis were the risk factors for
RRD development. The posterior location of inflam-
mation may lead to structural alterations of the vitr-
eous, and vitreous gel shrinkage4 as well as to
development of tractional forces especially at poorly
perfused areas with, all of which might be associated
with development of retinal tears.
ARN was the most common single uveitis entity
found in patients with uveitis and RRD. In our
study, the incidence of RRD in ARN was 38%, which
is consistent with recent studies that indicate the RRD
occurrence from 20% to 85% of eyes.27–32
Prior intravitreal injections might form a predispos-
ing factor for RRD development. This was already
noted in previous reports33,34 which hypothesized
that intravitreal injection might induce PVD and
thereby increase a risk of retinal tears. In our study,
with the application of multivariate analysis, we can-
not confirm this association. The intravitreal injections
in uveitis are mostly given to patients with posterior
and panuveitis, whilst posterior and panuveitis also
form a high-risk factor for RRD. When solely patients
with posterior and panuveitis were compared for the
number of prior intravitreal injections, no differences
were observed in patients with and without RRD
(P = 0.078).
The visual prognosis of RRD complicating uveitis
was in our series poor despite the anatomical success
obtained in the majority of patients. Silicone oil was
used in majority of patients and though this tampo-
nade induces retinal stability, silicone oil itself
decreases visual function and increases complication
such as cataract, glaucoma, band keratopathy.
The limitations of our study include its retrospective
character, limited number of patients, and a possible
selection bias towards more severe. Due to the limited
number of patients, the efficacy of specific treatment
approaches cannot be evaluated.
In conclusion, our data show that uveitis itself is a risk
factor for the development of RRD, especially posterior
uveitis and panuveitis. Infectious uveitis and specifically
ARN were associated with the development of RRD.
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